Traders Buy Gilead Sciences (GILD) on Weakness
Traders purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Friday. $133.52 million flowed into the stock on the tick-up and $78.12 million flowed out of the stock on the tick-down, for a money net flow of $55.40 million into the stock. Of all stocks tracked, Gilead Sciences had the 10th highest net in-flow for the day. Gilead Sciences traded down ($0.04) for the day and closed at $79.02
A number of brokerages recently weighed in on GILD. BidaskClub cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday. Leerink Swann upped their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research report on Thursday, October 19th. Maxim Group reaffirmed a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Mizuho upped their price target on shares of Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Finally, Bank of America decreased their price target on shares of Gilead Sciences from $87.00 to $86.00 and set a “neutral” rating for the company in a research report on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $85.03.
The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The stock has a market cap of $103,190.00, a PE ratio of 8.99, a P/E/G ratio of -1.58 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The business had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. During the same quarter last year, the company posted $2.75 earnings per share. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current year.
The business also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were given a dividend of $0.52 per share. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.63%. Gilead Sciences’s payout ratio is 23.66%.
In other news, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the transaction, the executive vice president now owns 77,363 shares of the company’s stock, valued at $5,788,299.66. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the sale, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 in the last ninety days. Corporate insiders own 1.30% of the company’s stock.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Welch Investments LLC acquired a new stake in Gilead Sciences during the third quarter worth about $108,000. Wealthcare Advisory Partners LLC acquired a new stake in Gilead Sciences during the third quarter worth about $133,000. Horan Capital Advisors LLC. acquired a new stake in Gilead Sciences during the third quarter worth about $144,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Gilead Sciences during the second quarter worth about $147,000. Finally, Hanson & Doremus Investment Management raised its stake in Gilead Sciences by 806.5% during the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 1,613 shares during the period. Hedge funds and other institutional investors own 75.94% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://theolympiareport.com/2018/01/12/traders-buy-gilead-sciences-gild-on-weakness.html.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with Analyst Ratings Network's FREE daily email newsletter.